Stroke patients being prescribed ineffective drugs: AIIMS

Image
IANS New Delhi
Last Updated : Jul 14 2015 | 7:13 PM IST

Over eight lakh stroke patients in north India are being prescribed neuroprotective drugs which are not recommended by clinical practice guidelines set by the world bodies, an AIIMS study has revealed.

Citicoline, Piracetam, and Edaravone are the three drugs being prescribed to the stroke patients over the years in spite of the directions from the medical bodies against prescribing them as they have been found non-effective in stroke patients.

The two-year study of the medicines being prescribed to the stroke patients also revealed that medicine such as blood pressure lowering agents - statins, and anti-platelet agents which were found being actually effective were not being administered to patients.

A report from Indian Council of Medical Research (ICMR) indicated that in 2004 there were approximately 9,30,985 cases of stroke in the country with 6,39,455 deaths.

The National Commission on Macroeconomics and Health, India, recently estimated 1.67 million stroke cases in the country by 2015.

"Both specialist and private hospitals are associated with higher prescription of "ineffective neuroprotective" drugs in both poor and rich patients," the AIIMS study's report exclusively given to the IANS.

Kameshwar Prasad, head of Neurology at AIIMS and under whom the research was conducted, said, "The reasons are yet to be studied but the speculative reasons are that often the doctors miss particular medicines due to the constant pressure on them and also they forget about it."

He said the other speculative reason behind the issue was that even the patients are not aware of the effective medicines, which is actually very necessary.

Prasad also said though the study only revealed about north India, the situation may be much more worse in other parts of India, as they were out of the direct purview of the union health ministry.

"Once we get to know about the total spending on the medicines incurred by the health ministry only then we can get to know how much of money is spent on buying the ineffective drugs in the country," he told IANS.

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jul 14 2015 | 7:02 PM IST

Next Story